The anaplastic lymphoma kinase (ALK) fusion gene, found in 3–5% of NSCLC, is a driver mutation for which target therapies are available, such as crizotinib, first-in-class, multitargeted tyrosine kinase inhibitor (TKI) [3]. This evidence concerns the gene ALK and non-small cell lung carcinoma.